<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00327054</url>
  </required_header>
  <id_info>
    <org_study_id>05201MED(Grant Fund#1VJ)</org_study_id>
    <nct_id>NCT00327054</nct_id>
  </id_info>
  <brief_title>Effectiveness of Nigella Sativa (Kalonji) Seed in Dyslipidemia</brief_title>
  <official_title>Effectiveness of Nigella Sativa (Kalonji) Seed in Dyslipidemia: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study.&#xD;
&#xD;
      The aim of the investigators' study is to evaluate the effectiveness of nigella sativa seed&#xD;
      in the treatment of dyslipidemia.&#xD;
&#xD;
      Dyslipidemia is a common risk factor for cardiovascular disease, the leading cause for&#xD;
      morbidity and mortality among patients.&#xD;
&#xD;
      Nigella sativa is an easily available and acceptable remedy to treat dyslipidemia and at a&#xD;
      low cost.&#xD;
&#xD;
      It is expected that by scientifically determining the effectiveness of this intervention it&#xD;
      will lead to its widespread use.&#xD;
&#xD;
      This will provide a low cost alternative to treat dyslipidemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Pakistan is a developing country with limited resources and a high prevalence of&#xD;
           dyslipidemia.&#xD;
&#xD;
        -  Nigella sativa is a small plant originating in the Middle East and is found abundantly,&#xD;
           growing wild in Egypt, Asiatic Turkey and the Balkan States.&#xD;
&#xD;
        -  The seed extracts from this plant are used by herbalists in the treatment of several&#xD;
           medical disorders including dyslipidemia.&#xD;
&#xD;
      OBJECTIVE:&#xD;
&#xD;
      To determine the effectiveness of the nigella sativa seed in the control of dyslipidemia in&#xD;
      adults. This is a pilot study.&#xD;
&#xD;
      METHODOLOGY&#xD;
&#xD;
      DESIGN&#xD;
&#xD;
      Double blind, randomized, controlled trial&#xD;
&#xD;
      Inclusion Criteria:&#xD;
&#xD;
        -  Adult (18 years or older) men and women who have serum cholesterol &gt; 180 mgs/ dls&#xD;
&#xD;
        -  Who consent to participate&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        -  Patients with known Diabetes Mellitus&#xD;
&#xD;
      Primary Endpoint&#xD;
&#xD;
      The primary end point for the trial is serum LDL cholesterol concentration measured at six&#xD;
      weeks after intervention.&#xD;
&#xD;
      Secondary Endpoint&#xD;
&#xD;
        -  Serum total cholesterol concentrations measured at six weeks after intervention&#xD;
&#xD;
        -  Serum concentrations of HDL cholesterol measured at six weeks after intervention&#xD;
&#xD;
        -  Serum concentrations of Triglyceride measured at six weeks after intervention&#xD;
&#xD;
        -  Serum concentrations of Blood sugar measured at six weeks after intervention&#xD;
&#xD;
        -  Changes in Serum Transminase and Serum Creatinine with six weeks of intervention&#xD;
&#xD;
      Intervention Group Recommended&#xD;
&#xD;
        -  Dietary changes&#xD;
&#xD;
        -  Lifestyle changes&#xD;
&#xD;
        -  Nigella sativa seed as intervention.&#xD;
&#xD;
      Intervention details:&#xD;
&#xD;
        -  Quantity: Two capsules of crushed nigella sativa seeds 500 mgs each&#xD;
&#xD;
        -  Frequency: Twice daily&#xD;
&#xD;
        -  Timing: After meals&#xD;
&#xD;
        -  Duration: Six weeks&#xD;
&#xD;
      Control Group Recommended&#xD;
&#xD;
        -  Dietary changes&#xD;
&#xD;
        -  Lifestyle changes&#xD;
&#xD;
        -  Capsules containing Calcium Lactate&#xD;
&#xD;
      Dietary Advice&#xD;
&#xD;
      Study subjects will receive advice from the Principal Investigator (PI)&#xD;
&#xD;
        -  Eat low fat, low cholesterol foods&#xD;
&#xD;
        -  Cut down on high fat food (fatty meats and bakery goods)&#xD;
&#xD;
        -  Use low fat cooking methods (Use nonstick pans, barbecue, roast, boil)&#xD;
&#xD;
        -  Avoid alcohol consumption&#xD;
&#xD;
        -  Eat more fruits, vegetables and whole grains&#xD;
&#xD;
        -  Subjects of both groups will be given standard low cholesterol diet sheet as well&#xD;
&#xD;
      Exercise&#xD;
&#xD;
      Subjects in both groups will be advised to take a brisk 30 minute walk for 5 days in a week&#xD;
      on empty stomach or one hour after having a meal.&#xD;
&#xD;
      LABORATORY INVESTIGATIONS&#xD;
&#xD;
      For lab investigations venous blood specimens will be collected for the following tests. The&#xD;
      tests will be performed on 12 hour fasting samples to assess the primary and secondary&#xD;
      outcomes.&#xD;
&#xD;
        -  Total Cholesterol&#xD;
&#xD;
        -  Low Density Lipoprotein (LDL)&#xD;
&#xD;
        -  High Density Lipoprotein (HDL)&#xD;
&#xD;
      Other investigations&#xD;
&#xD;
        -  Triglycerides&#xD;
&#xD;
        -  Fasting blood glucose (FBS)&#xD;
&#xD;
        -  Creatinine SGPT (ALT)&#xD;
&#xD;
      IDENTIFICATION OF STUDY SUBJECTS&#xD;
&#xD;
      Study subjects will be identified from executive and family medicine clinics within AKUH.&#xD;
      Individuals fulfilling the inclusion criteria will be informed about the study and asked to&#xD;
      participate.&#xD;
&#xD;
      INFORMED CONSENT&#xD;
&#xD;
        -  The participants will be informed of all possible expected benefits and possible harm&#xD;
           ensuing from the study&#xD;
&#xD;
        -  Written informed consent will be obtained from the study subjects addressing the ethical&#xD;
           concerns of the relevant authority&#xD;
&#xD;
      RANDOMIZATION&#xD;
&#xD;
        -  A randomized controlled design will be used for this trial&#xD;
&#xD;
        -  Randomization will be done to give an equal chance to eligible subjects of being&#xD;
           assigned to either group.&#xD;
&#xD;
        -  A randomization plan with a block size of four will be used to assign subjects to the&#xD;
           intervention and control groups&#xD;
&#xD;
        -  This will be done in order to achieve an equal number of participants in both the groups&#xD;
&#xD;
        -  A Co-Investigator will create subject identification numbers and assign group according&#xD;
           to randomization.&#xD;
&#xD;
      FOLLOW-UP &amp; DATA COLLECTION&#xD;
&#xD;
        -  Baseline data including information on height, weight, blood pressure, blood sugar&#xD;
           fasting, serum cholesterol, HDL, LDL, triglycerides and serum creatinine will be&#xD;
           collected prior to starting intervention&#xD;
&#xD;
        -  Subjects in both study groups will be telephoned, at an interval of 10 days by the study&#xD;
           assistant to ensure patient compliance&#xD;
&#xD;
        -  At the end of six weeks period, a fasting blood sample will be taken from the study&#xD;
           subjects for measuring total cholesterol, LDL and HDL concentrations, serum&#xD;
           triglycerides, blood sugar fasting and serum creatinine.&#xD;
&#xD;
        -  A food diary combining groups of foods with similar nutrient content and dietary use&#xD;
           will be given to study subjects&#xD;
&#xD;
        -  Participants will record daily food intake initially and at the end of the trial period&#xD;
&#xD;
        -  Patients' Body Mass Index (BMI), waist hip ratio and blood pressure will be recorded at&#xD;
           baseline and at the end of the study.&#xD;
&#xD;
      ETHICAL ISSUES:&#xD;
&#xD;
        -  Subjects in both groups of the study will be given standard dietary advice, which is&#xD;
           recommended by National Cholesterol Education Program (NCEP) in cases fitting the&#xD;
           inclusion criteria of this proposed study.&#xD;
&#xD;
        -  In studies conducted previously, the nigella sativa seed has shown to demonstrate&#xD;
           protective effects against nephrotoxicity and hepatotoxicity induced by either disease&#xD;
           or chemicals.&#xD;
&#xD;
        -  However, in case adverse events are observed, the intervention with nigella sativa will&#xD;
           be stopped for that particular individual.&#xD;
&#xD;
      SAMPLE SIZE CONSIDERATIONS&#xD;
&#xD;
      This is a pilot study and will include 80 patients. Half will get N. Sativa seed capsules and&#xD;
      the rest will get calcium lactate placebo capsules.&#xD;
&#xD;
      Analysis&#xD;
&#xD;
        -  In descriptive statistics, comparison of the two treatment groups would be done on&#xD;
           variables such as age and gender. The results will be mentioned in frequency and&#xD;
           percentages.&#xD;
&#xD;
        -  In univariate analysis t-test will be applied to detect a significant difference in the&#xD;
           primary outcome between the two groups.&#xD;
&#xD;
        -  For multivariate analysis, linear regression analysis will be used to identify variables&#xD;
           associated with the primary outcome (LDL concentration), and to control for confounding&#xD;
           factors. A similar process will be adopted for secondary outcome variables i.e., serum&#xD;
           total cholesterol concentrations and HDL.&#xD;
&#xD;
      SITE&#xD;
&#xD;
      Aga Khan University Hospital (AKUH), Karachi&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point for the trial is serum low-density lipoprotein (LDL) cholesterol concentration measured at six weeks after intervention.</measure>
    <time_frame>six weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum total cholesterol concentrations measured at six weeks after intervention</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of high-density lipoprotein (HDL) cholesterol measured at six weeks after intervention</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triglyceride concentrations measured at six weeks after intervention</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum blood sugar concentrations measured at six weeks after intervention</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure measured at six weeks after intervention</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum creatinine after six weeks intervention</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Hypertension</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Nigella sativa seed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nigella sativa seed</intervention_name>
    <arm_group_label>Nigella sativa seed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (18 years or older) men and women&#xD;
&#xD;
          -  Serum cholesterol &gt; 180 mgs/dl&#xD;
&#xD;
          -  Provide Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waris - Qidwai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aga Khan University, Karachi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aga Khan University</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Ismail J, Jafar TH, Jafary FH, White F, Faruqui AM, Chaturvedi N. Risk factors for non-fatal myocardial infarction in young South Asian adults. Heart. 2004 Mar;90(3):259-63.</citation>
    <PMID>14966040</PMID>
  </reference>
  <reference>
    <citation>Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother Res. 2003 Apr;17(4):299-305. Review.</citation>
    <PMID>12722128</PMID>
  </reference>
  <reference>
    <citation>Zaoui A, Cherrah Y, Alaoui K, Mahassine N, Amarouch H, Hassar M. Effects of Nigella sativa fixed oil on blood homeostasis in rat. J Ethnopharmacol. 2002 Jan;79(1):23-6.</citation>
    <PMID>11744291</PMID>
  </reference>
  <reference>
    <citation>El-Saleh SC, Al-Sagair OA, Al-Khalaf MI. Thymoquinone and Nigella sativa oil protection against methionine-induced hyperhomocysteinemia in rats. Int J Cardiol. 2004 Jan;93(1):19-23.</citation>
    <PMID>14729430</PMID>
  </reference>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>May 16, 2006</study_first_submitted>
  <study_first_submitted_qc>May 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2006</study_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2015</last_update_posted>
  <keyword>Dyslipidaemia</keyword>
  <keyword>Herbal medicine</keyword>
  <keyword>Home remedy</keyword>
  <keyword>Alternative medicine</keyword>
  <keyword>Metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

